Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation
Catheterization and Cardiovascular Interventions2009Vol. 75(3), pp. 317–325
Citations Over TimeTop 12% of 2009 papers
Siniša Stojković, Miodrag Ostojić, Milan Nedeljković, Goran Stanković, Branko Beleslin, Vladan Vukcevic, Dejan Orlić, Aleksandra Arandjelovic, Jelena Kostić, Miodrag Dikic, Miloje Tomašević
Abstract
This study showed that the administration of oral rapamycin (2 mg/day, without loading dose) during 30 days after stent implantation significantly reduces angiographic and clinical parameters of restenosis.
Related Papers
- → A prospective multicentre registry, evaluating real-world usage of the Tryton side branch stent: results of the E-Tryton 150/Benelux registry(2012)27 cited
- → Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study(2016)17 cited
- → Orbital Atherectomy for the Treatment of Long (≥25–40 mm) Severely Calcified Coronary Lesions: ORBIT II Sub-Analysis(2019)7 cited
- → Same or Different Drug‐Eluting Stent Re‐Implantation for Drug‐Eluting Stent Restenosis: An Assessment Including Second‐Generation Drug‐Eluting Stents(2016)2 cited
- [First in man registry with a bioabsorbable polymer based sirolimus-eluting stent: six month angiographic and 12 month clinical results (MedistreExcel Drug-eluting STent TRiAL)].(2007)